Avantor Appoints Gladys Wang as VP of Bioprocessing Commercial for AMEA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Yahoo Finance
- Leadership Change: Avantor has appointed Gladys Wang as Vice President of Bioprocessing Commercial for Asia, Middle East, and Africa, leveraging over 20 years of life sciences and commercial leadership experience to drive business expansion and customer success in the region.
- Market Expansion Strategy: Gladys will focus on enhancing collaboration with biopharma manufacturers and key opinion leaders, aiming to strengthen strategic partnerships within the bioprocessing ecosystem through customer-centric strategies and cross-market collaboration.
- Background Experience: Prior to joining Avantor, Gladys held senior leadership roles at top life sciences organizations, successfully accelerating Asia-Pacific expansion and achieving significant business growth, demonstrating the effectiveness of her disciplined market-entry strategies.
- Future Outlook: Gladys expressed her commitment to deepening collaboration, enhancing customer experience, and empowering teams to deliver meaningful impact across the bioprocessing value chain, further solidifying Avantor's market position in the AMEA region.
AVTR
$11.28+Infinity%1D
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 13.86 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 11.270
Low
12.00
Averages
13.86
High
17.00
Current: 11.270
Low
12.00
Averages
13.86
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
